Min, I have posted more facts directly related to PS Targeting and I say * IP Assets * which INCLUDES Bavituximab ...though it does not end with Bavituximab
Within my past dozen posts I specifically already gave examples on how Bavi patents could be extended and when do those patents expire? I have posted that also
How about reminding folks PS Targeting will include dozens of targets, SURPRISING COMBINATIONS ...eh?
Betabodies, directly related to PS Trgeting .."as of now" expires Dec 10, 2027
If one comes thru my posts, you will realize that 2027 will be extended as well
The onion is being peeled back one later at a time....and I have hundreds of layers
___
Constructs binding to phosphatidylserine and their use in disease treatment
Abstract
Disclosed are new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof. The new constructs effectively bind phosphatidylserine targets in disease and enhance their destruction, and can also specifically deliver attached imaging or therapeutic agents to the disease site. Also disclosed are methods of using the new construct compositions, therapeutic conjugates and combinations thereof in tumor vasculature targeting, cancer diagnosis and treatment, and for treating viral infections and other diseases.
Images (28)
Classifications
C07K14/775 Apolipopeptides
View 20 more classifications
US20060228299A1
United States
Download PDF Find Prior Art Similar
Inventor
Philip Thorpe
Troy Luster
Steven King
Current Assignee
MIDCAP FUNDING III LLC
Peregrine Pharmaceuticals Inc
University of Texas System
Worldwide applications
2006 WO NZ DK AU ES SI EP US JP CN CA CN SG CN 2007 IL 2012 JP 2014 HK 2015 US HK 2016 US
Application US11/339,392 events
2005-01-24
Priority to US64633305P
2006-01-24
Application filed by Peregrine Pharmaceuticals Inc, University of Texas System
2006-10-12
Publication of US20060228299A1
2015-02-17
Publication of US8956616B2
2015-02-17
Application granted
2019-11-11
Application status is Active
2027-12-10
Adjusted expiration
_________
MidCap Financial is managed by Apollo Capital Management, L.P., a subsidiary of Apollo Global Management, LLC, pursuant to an investment management ...
John Springs Stafford in a bit of trouble it seems ....eh?
________
